Revolutionize Antibody Selection - meet selma
Universally applicable, selma streamlines high-throughput screening by capturing antibodies in their natural form, allowing for early characterization and direct production without recloning. Flexible and efficient, it enables selection from 1 million antibody-producing cells per screening.
- Mammalian cell display system to capture secreted antibodies
- Flexible and infinite screening options for isotypes, cross-reactivities, affinities, and antigenic variants
- High-throughput sorting and single cell plating
Benefits of Camelid antibodies
Camelid nanobodies are only one-tenth the size of a conventional antibody (12-15 kDa versus 150 kDa), making them the smallest antigen-binding moiety found in nature. Based on their single antigen binding site, they can adopt a specific finger-like structure to recognize and bind hidden or buried target epitopes.
- Superior binding affinities
- Ease of humanization
- Low immunogenicity
- Deep tissue penetration
- Excellent solubility and high stability
- Easy and cheap manufacturing
These properties can be translated into novel forms of antibody-based diagnostic products and drug therapies.
Epitope-specific immunization with viral carriers
We base our immunization strategy onto the most efficient danger signals to the mammalian immune system: viruses. By combining efficient surface-related epitopes with a viral particle system originated from the hamster polyomavirus, we are able to perform a hyper-immunization schedule, extraordinarily faster than conventional immunization strategies. We guarantee a surface-related presentation of the target epitope within the viral backbone.
- AI-based target and epitope profiling
- Surface-related epitope design
- Generation of unique viral-based immunoconjugates
This flexibility provides the advantage of inducing a highly potent and antigen specific immune response to the native target.
Human antibody development
Human antibodies are essential drugs for manifold diseases and well accepted therapeutic formats. With our in-house developed in vitro immunization process we are able to activate human naïve B lymphocytes antigen-specifically within 12 days and fuse them afterwards to obtain immortal hybridoma cell pools. Target-specific screening of candidates is performed with selma.
- In vitro immunization with human B cells to create antigen-specific human cell pools
- Induction of different human IgG isotypes
- Selma selection and screening for high-performance binders
Our Publications
- Meet selma: Novel antibody generation four times fasterThis new/era/mabs article published in Research Features highlights the benefits working with our platform.
- A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell lineThis new/era/mabs article published in nature scientific reports describes our new antibody discovery platform selma.
- Selection of Antibodies Using selma TechnologyThis new/era/mabs white paper describes highlights and use cases of selma.
- How Nanobodies Open New GatesThis new/era/mabs white paper describes workflows and use cases for camelid antibodies.
- selma Technology & Camelid Phage Display for the Discovery of Anti-SARS-CoV-2 AntibodiesThis new/era/mabs scientific poster shows selma for the selection of human antibodies and generation of SARS-CoV-2 camelid antibodies.
